Drugs that may harm bone: Mitigating the risk

Area of Science:

• Pharmacology
• Bone Metabolism
• Geriatric Medicine

Background:

• Several common drug classes are associated with adverse effects on bone density.
• Osteoporosis is a significant public health concern, particularly in aging populations.
• Medication-induced bone loss can increase fracture risk.

Purpose of the Study:

• To highlight common medications with detrimental effects on bone.
• To emphasize the importance of monitoring bone health in patients using these drugs.
• To provide recommendations for mitigating medication-related bone loss.

Main Methods:

• Review of pharmacological agents known to impact bone metabolism.
• Identification of drug classes with established adverse skeletal effects.
• Synthesis of current clinical guidelines for bone health management.

Main Results:

• Glucocorticoids, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), certain antiepileptic drugs, and aromatase inhibitors were identified as major contributors to bone loss.
• These medications can negatively impact bone mineral density and increase fracture risk.
• The mechanisms of bone impairment vary across drug classes.

Conclusions:

• Healthcare providers must proactively assess and monitor bone health in patients prescribed these medications.
• Interventions including calcium and vitamin D supplementation, weight-bearing exercise, and pharmacotherapy for osteoporosis prevention are crucial.
• Early detection and management can reduce the incidence of fractures and improve patient outcomes.